Terumo Aortic Announces Launch of Industry-first Global Endovascular Registry

November 18, 2019

Terumo Aortic today announced the launch of the company's global endovascular registry known as TiGER (Terumo Aortic Global Endovascular Registry).

TiGER is a global, prospective, multi-arm, multi-centre registry evaluating more than 1,000 patients over a period of 5 years. The study will collect a broad range of clinical evidence on the company's comprehensive thoracic and abdominal endovascular product portfolio.

At the recent European Investigators' Meeting, the TiGER Principal Investigator, Professor Vincent Riambau, Barcelona commented, "This is a truly unique registry encompassing the complete range of endovascular solutions for the entire aorta. This will provide an unparalleled perspective on the 'real world' results of aortic endovascular procedures."

The registry will begin enrolling patients across approximately 40 sites in Europe with plans to expand into additional geographies including the United States, Japan and Latin America.

Mark Miles, Chief Commercial Officer of Terumo Aortic added, "TiGER is the industry's first global registry evaluating patients across multiple aortic pathologies using both standard and custom endovascular technologies. This reinforces our commitment to transforming the treatment of aortic disease and serves as the model for an evidence-based approach required for broad adoption of innovative device solutions."

The launch of the TiGER Registry marks an important milestone for Terumo Aortic as it continues to expand its surgical, endovascular and hybrid businesses worldwide.

About Terumo Aortic

At Terumo Aortic, our mission is to transform the treatment of aortic disease worldwide. With our comprehensive portfolio of surgical, endovascular and hybrid technologies, we enable surgeons to find the right fit for each patient anatomy.

Notes to Editors

- Terumo Corporation of Japan, a global medical device company founded in 1921 currently has over 25,000 employees worldwide.
- Terumo acquired Vascutek Ltd. in 2002 and Bolton Medical, Inc. in 2017.
- Terumo Aortic has over 1,250 employees including 850 based in Glasgow, Scotland; 330 based in Sunrise, Florida and the remaining within direct European markets.

Media Contact

Corporate Communication Dept., Terumo Corporation

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.